Literature DB >> 12711484

Benign prostatic hyperplasia.

A Thorpe1, D Neal.   

Abstract

In both ageing men and women, there is an increasing incidence of lower urinary tract symptoms (LUTS) which are increasing. These infections have many possible causes, including smooth muscle dysfunction, neurological factors and benign prostatic hyperplasia. Up to 15% to 25% of men aged 50-65 years have LUTS of sufficient severity to interfere with their quality of life. Although benign prostatic hyperplasia is an important cause of these symptoms, and can have serious consequences, clinicians should be aware of these other causes so that the appropriate diagnosis is made before invasive treatments are started. New medical treatments, including alpha-adrenergic blocking agents and 5 alpha-reductase inhibitors mean that many men without complications such as infection, bleeding, or chronic retention, and with mild to moderate symptoms, should be managed in primary care. Combined local protocols between primary and secondary care will help to establish which men with persistent symptoms or complications need referral for a urological opinion to determine the need for further investigation and more invasive forms of management. We review the pathophysiology of the disease, and current approaches to investigation and management of this common problem.

Entities:  

Mesh:

Year:  2003        PMID: 12711484     DOI: 10.1016/S0140-6736(03)13073-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  57 in total

1.  The absence of voiding symptoms in men with a prostate-specific antigen (PSA) concentration of ≥3.0 ng/mL is an independent risk factor for prostate cancer: results from the Gothenburg Randomized Screening Trial.

Authors:  Maria Frånlund; Sigrid Carlsson; Johan Stranne; Gunnar Aus; Jonas Hugosson
Journal:  BJU Int       Date:  2012-04-30       Impact factor: 5.588

2.  A call for HoLEP: en-bloc vs. two-lobe vs. three-lobe.

Authors:  Frank Rücker; Karin Lehrich; Axel Böhme; Mario Zacharias; Sascha A Ahyai; Jens Hansen
Journal:  World J Urol       Date:  2021-01-24       Impact factor: 4.226

Review 3.  Drug-induced urinary retention: incidence, management and prevention.

Authors:  Katia M C Verhamme; Miriam C J M Sturkenboom; Bruno H Ch Stricker; Ruud Bosch
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

Review 4.  Lower Urinary Tract Symptoms Following Transurethral Resection of Prostate.

Authors:  Soo Jeong Kim; Omar Al Hussein Alawamlh; Bilal Chughtai; Richard K Lee
Journal:  Curr Urol Rep       Date:  2018-08-20       Impact factor: 3.092

5.  Experience with the combination of dutasteride and tamsulosin in the long-term management of benign prostatic hyperplasia.

Authors:  Bilal Chughtai; Dean S Elterman; Richard Lee; Alexis E Te; Steven A Kaplan
Journal:  Ther Adv Urol       Date:  2012-10

6.  Risk of prostate cancer associated with benign prostate disease: a primary care case-control study.

Authors:  Brian S Buckley; Marie Carmela M Lapitan; Colin R Simpson; Aziz Sheikh
Journal:  Br J Gen Pract       Date:  2011-11       Impact factor: 5.386

Review 7.  Silodosin in the treatment of benign prostatic hyperplasia.

Authors:  Maxime Rossi; Thierry Roumeguère
Journal:  Drug Des Devel Ther       Date:  2010-10-27       Impact factor: 4.162

8.  Analysis of the factors causing bladder irritation after transurethral resection of the prostate.

Authors:  Tae Im Kim; Jae Mann Song; Hyun Chul Chung
Journal:  Korean J Urol       Date:  2010-10-21

9.  The different reduction rate of prostate-specific antigen in dutasteride and finasteride.

Authors:  Yong Hyeuk Choi; Sung Yong Cho; In Rae Cho
Journal:  Korean J Urol       Date:  2010-10-21

10.  Vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.

Authors:  Hartmut Porst; Peter Sandner; Ernst Ulbrich
Journal:  Curr Urol Rep       Date:  2008-07       Impact factor: 3.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.